Sector News

Roche buys U.S.-based Kapa Biosystems

August 20, 2015
Life sciences
(MarketWatch) – Roche Holding AG (ROG.VX) Wednesday said it has bought a U.S. gene-technology company, the latest acquisition in the area by the Swiss pharmaceutical company.
 
Basel-based Roche said it will buy Kapa Biosystems Inc., based in Wilmington, Mass., for an undisclosed sum. The closely held U.S. company has been working on ways to accelerate research into genomes, the complete set of DNA with within a single cell.
 
Roche is interested in the area because it leads to a better understanding of the genetic roots of diseases by identifying genetic mutations. Genome research can affect the future ability to diagnose, monitor and treat cancer and other conditions.
 
Kapa’s protein-engineering technology allows for the generation and screening of large numbers of enzyme variants, Roche said. Tailored enzymes with improved performance for specific applications can be rapidly selected, speeding up product development time lines, the company added.
 
Last week, Roche said it was buying GeneWEAVE BioSciences, a California-based developer of clinical microbiology with diagnostics solutions, for an initial $190 million.
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”